SARS-CoV-2 coronavirus variants B.1.351 and P.1 escape from neutralizing antibodies

B.1.351, Coronavirus, Health, Infection, P.1, Science, Testing, Vaccine

“In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. Moreover, entry of these variants was less efficiently inhibited by plasma from convalescent COVID-19 patients and sera from BNT162b2-vaccinated individuals. These results suggest that SARS-CoV-2 may escape neutralizing antibody responses, which has important implications for efforts to contain the pandemic.” report


Photo by Mufid Majnun on Unsplash

** This post was originally published on April 11, 2021 **